Amprius Selected for Amazon Devices Climate Tech Accelerator
Amprius was selected through a competitive process prioritizing climate impact and innovation potential, based on the promise of its SiCore® battery platform. SiCore delivers up to 80% higher energy density than conventional lithium-ion batteries, enabling longer runtimes, faster charging, and light-weight design to support more energy-efficient device platforms.
'Participating in the Amazon Devices Climate Tech Accelerator gives us a valuable opportunity to engage with Amazon's technical and sustainability teams that are working on millions of devices worldwide,' said Dr. Kang Sun, CEO of Amprius Technologies. 'We're particularly interested in exploring how our silicon anode technology could provide more efficient and lightweight energy solutions in industrial, consumer electronics, and mobility-focused platforms.'
'We're excited to welcome Amprius to the cohort and explore how their battery innovation can support our goals for sustainable product performance across Amazon Devices,' stated Juliette Devaney, Head of Amazon Devices Climate Tech Accelerator.
Amprius' participation reflects the important role advanced batteries play in accelerating electrification and reducing carbon emissions across industries. As demand grows for lighter, more energy-dense solutions in sectors such as light electric vehicles, aviation, and robotics, Amprius' batteries offer a path to higher system efficiency and lower environmental impact, making programs like this a valuable forum for exploring future applications.
For more information, please visit the Amprius investor relations website at ir.amprius.com.
About Amprius Technologies, Inc.
Amprius Technologies, Inc. is a leading manufacturer of high-energy and high-power lithium-ion batteries, producing the industry's highest-known energy density cells. The Company's commercially available SiCore® and SiMaxx™ batteries deliver up to 450 Wh/kg and 1,150 Wh/L, with third-party validation of 500Wh/kg and 1,300 Wh/L. The Company's corporate headquarters is in Fremont, California, where it maintains an R&D lab and a MWh scale manufacturing facility for the fabrication of silicon anodes and cells. To serve customer demand, Amprius entered into several agreements to secure over 1.8 GWh of contract manufacturing capacity. For additional information, please visit amprius.com. Also, see the Company's LinkedIn page.
Forward-Looking Statements
This press release includes 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements may be identified by the use of words such as 'estimate,' 'plan,' 'project,' 'forecast,' 'intend,' 'expect,' 'anticipate,' 'believe,' 'seek' or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the performance of Amprius' products, the benefits of Amprius' products to its customers and the industry, the potential applications and addressable market of Amprius' products, and the ability of Amprius' technology to help reduce carbon emissions. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Amprius' management and are not predictions of actual performance. Actual results could differ materially from these forward-looking statements as a result of certain risks and uncertainties. These forward-looking statements are subject to a number of risks and uncertainties, including Amprius' liquidity position; risks related to the rollout of Amprius' business and the timing of expected business milestones; Amprius' ability to commercially produce high performing batteries; the effects of competition on Amprius' business; supply shortages in the materials necessary for the production of Amprius' products; and changes in domestic and foreign business, market, financial, political and legal conditions. For more information on these risks and uncertainties that may impact the operations and projections discussed herein can be found in the documents we filed from time to time with the Securities and Exchange Commission (the 'SEC'), all of which are available on the SEC's website at www.sec.gov. There may be additional risks that Amprius does not presently know or that Amprius currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Amprius' expectations, plans or forecasts of future events and views as of the date of this press release. These forward-looking statements should not be relied upon as representing Amprius' assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Except as required by law, Amprius specifically disclaims any obligation to update any forward-looking statements.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?
Key Points Hims & Hers Health continues to post robust growth. Shares sold off, however, after revenue missed analyst expectations. The stock is still reasonably valued given its growth prospects. 10 stocks we like better than Hims & Hers Health › Hims & Hers Health (NYSE: HIMS) is one of the most volatile stocks on the market at the moment, prone to big swings in either direction. This is true even intraday, as the stock plunged following the company's second-quarter results, only to rally back, only to plunge again. As of this writing, the stock is still trading up more than 130% this year. Let's take a closer look at the most recent earnings results for this telehealth company focused on providing accessible and affordable healthcare solutions for various health and wellness needs, and its prospects. Who knows, you might want to jump in on this somewhat volatile growth stock. Hims saw strong revenue growth in Q2 Hims & Hers continued to deliver outstanding revenue growth in Q2, with sales climbing 73% year over year to $544.8 million. That was toward the high end of its forecast for revenue of $530 million to $550 million, but it missed analyst expectations for revenue of $552 million. Monthly online revenue per subscriber jumped 30% to $74 per month, while the number of subscribers climbed 31% to nearly 2.44 million. The company said that the number of subscribers in both oral weight loss and dermatology grew more than 55% in the quarter. Customers using at least one personalized subscription increased by 89% to 1.5 million, representing more than 60% of the Hims & Hers subscriber base. It said that 70% of new patients who join the platform use a personalized treatment plan, and that the number of subscribers using a personalized treatment plan to treat multiple conditions skyrocketed 170% to more than 500,000. Revenue from GLP-1 weight loss drugs fell from $230 million in Q1 to $190 million in Q2, after Novo Nordisk ended a partnership with the telehealth company. Nonetheless, it still expects to generate $725 million of revenue this year from weight loss drugs, led by oral weight loss products and personalized doses. Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending jumped 50% to nearly $218 million. Marketing expenses took up 40% of revenue in the quarter, though that was down from 46% a year ago, so the company continues to see leverage in this area despite the increased spending. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) surged to $82.2 million from $39.3 million a year ago. Adjusted earnings per share (EPS) came in at $0.17, topping the $0.15 analyst consensus as compiled by LSEG. Metric Q1 Results Growth (YOY) Revenue $544.8 million 73% Monthly online revenue per subscriber $74 30% Subscribers 2.44 million 31% Adjusted EBITDA $82.2 million 109% Adjusted EPS $0.17 183% Marketing expense $231 million 77% Marketing as % of revenue 40% (600 basis points) Gross margin 76% (500 basis points) Data source: Hims & Hers Health. YOY = year over year. Looking ahead, Hims & Hers maintained its forecast for 2025 revenue to be between $2.3 billion and $2.4 billion, equal to growth of 56% to 63%. It also kept its adjusted EBITDA guidance of $295 million to $335 million. For Q3, it projected revenue of between $570 million and $590 million, and adjusted EBITDA of $60 million to $70 million. The company is starting to look toward international expansion to bolster growth. It will begin by focusing on Canada next year, while its acquisition of Zava in July will help it expand into Europe. It also anticipates entering the Latin American and Asian markets in the coming years. Hims & Hers also continues to expand into new areas. It will launch hormonal health soon, starting with lab testing. The company believes this will help it reach its targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA in 2030. Is the stock a buy? Hims & Hers continues to be a growth engine. Even though there's been some disruption from its spat with Novo Nordisk, it is still seeing strong growth across different health categories. With the company moving into new areas, like hormonal health and longevity, and looking to expand internationally, it has a lot of growth opportunities ahead. Meanwhile, with the majority of its subscribers on personalized treatment plans, it has a pretty sticky user base. From a valuation standpoint, the stock trades at a forward price-to-earnings (P/E) ratio of around 55 based on the analyst consensus for 2025. But its forward price/earnings-to-growth ratio (PEG) is under 0.6, and stocks with PEG ratios below 1 are usually considered undervalued. Given that it operates a subscription business with high gross margins, you can also look at the stock from a price-to-sales perspective; on that front, it trades at a multiple of 5.5 times 2025 analyst estimates. Overall, I'd say, based on the type of business the company is in, that it's still reasonably priced. However, it's still a volatile stock that carries some risk depending on what happens in the weight loss segment. Still, I really like its international opportunity, and think Hims & Hers Health could have solid long-term upside from here. Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Geoffrey Seiler has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills? was originally published by The Motley Fool 登入存取你的投資組合
Yahoo
39 minutes ago
- Yahoo
This Top Warren Buffett Stock Continues to Deliver an Impressive Performance
Key Points Occidental Petroleum is one of Berkshire Hathaway's largest holdings. The oil company recently reported solid second-quarter results. It's making excellent progress on its plans to repay debt and grow shareholder value. 10 stocks we like better than Occidental Petroleum › Warren Buffett's company, Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B), continues to be a big believer in Occidental Petroleum (NYSE: OXY). It's easy to see why when looking at the oil giant's recently reported second-quarter results. The company delivered strong performance across the board despite lower oil and gas prices during the period. This consistent execution, even amid market volatility, gives Occidental Petroleum a solid foundation to grow shareholder value for Berkshire Hathaway and other investors in the years ahead. Drilling down into Occidental Petroleum's second-quarter results Occidental Petroleum produced $396 million, or $0.39 per share, of adjusted income during the second quarter. That was down from the $860 million, or $0.87 per share, it earned in the first quarter. The culprit was lower commodity prices. Occidental posted $934 million of pre-tax income in its oil and gas segment, down from $1.7 billion in the first quarter, due primarily to lower oil and gas prices. The average global price of crude oil was 10% below the first quarter's level, while the price of domestic natural gas tumbled 45%. Despite these lower prices, Occidental delivered higher volumes and strong results from its midstream and marketing segment. The company produced 1.4 million barrels of oil equivalent (BOE) per day, exceeding the mid-point of its guidance, while midstream and marketing earnings came in above the high-end of expectations. The company's chemicals business (OxyChem) also delivered solid results that were on par with its first-quarter performance. Additionally, strong well performance and enhanced operational efficiency supported robust cash generation. Operating cash flow before working capital adjustments was $2.6 billion, and free cash flow totaled $700 million, both slightly lower than the previous quarter. More progress on its debt-reduction plan Occidental Petroleum used its healthy free cash flow to pay its dividend and reduce debt. The company also continued to sell noncore assets to accelerate its debt-reduction efforts. It has secured $950 million of additional asset sales since the start of the second quarter. Those sales included $370 million of noncore and select non-operating Permian Basin upstream assets that closed during the quarter. Occidental also recently agreed to sell some gas-gathering assets in the Midland Basin to midstream company Enterprise Products Partners for $580 million. Those sales added to the $1.3 billion of noncore-asset sales it closed during the first quarter. The company has now agreed to sell $4 billion of assets since announcing its deal for CrownRock in late 2023, which has it closing in on the low end of its $4.5 billion to $6 billion target range. The energy company has used a combination of excess free cash and asset-sale proceeds to repay $3 billion of debt so far this year. Since July 2024, it has retired $7.5 billion of debt, saving it $410 million in annual interest expenses. The company has now significantly exceeded its target of delivering at least $4.5 billion of debt reduction within a year of closing its CrownRock deal. More positive catalysts ahead Occidental expects to continue using its excess free cash flow after paying dividends and noncore-asset sales to repay debt. It still has approximately $1.6 billion of 2026 debt maturities to address, as well as another $1.5 billion coming due in 2027. The company shouldn't have a problem paying off that debt, given the anticipated surge in its free cash flow from non-oil sources. The company estimates that a combination of interest expense savings, incremental earnings from upcoming chemicals projects, and midstream contract expirations will boost its free cash flow by $1 billion in 2026 and by an additional $500 million in 2027. As its debt continues to fall, Occidental will be positioned to return more cash to investors, beyond its dividend. It plans to eventually resume share repurchases and the redemption of Berkshire's preferred equity investment that it made in 2019 to support the company's acquisition of Anadarko Petroleum. A well-oiled machine Warren Buffett's Berkshire Hathaway has made a major bet on Occidental's ability to execute its plans to grow shareholder value. The company owns nearly 27% of the oil company's outstanding shares. That position is worth almost $12 billion (approximately 4% of Berkshire's investment portfolio), making it the seventh-largest holding. Occidental's strong second-quarter showing and progress on its debt-reduction plan prove that Buffett's company has made a smart investment. The oil company is in an excellent position to grow shareholder value in the future, despite the continued volatility of crude oil prices. Should you buy stock in Occidental Petroleum right now? Before you buy stock in Occidental Petroleum, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Occidental Petroleum wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Matt DiLallo has positions in Berkshire Hathaway and Enterprise Products Partners. The Motley Fool has positions in and recommends Berkshire Hathaway. The Motley Fool recommends Enterprise Products Partners and Occidental Petroleum. The Motley Fool has a disclosure policy. This Top Warren Buffett Stock Continues to Deliver an Impressive Performance was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Primo Brands Second Quarter 2025 Earnings: Misses Expectations
Explore Primo Brands's Fair Values from the Community and select yours Primo Brands (NYSE:PRMB) Second Quarter 2025 Results Key Financial Results Revenue: US$1.73b (up 32% from 2Q 2024). Net income: US$30.5m (down 44% from 2Q 2024). Profit margin: 1.8% (down from 4.1% in 2Q 2024). EPS: US$0.081 (down from US$52.89 in 2Q 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Primo Brands Revenues and Earnings Miss Expectations Revenue missed analyst estimates by 4.7%. Earnings per share (EPS) also missed analyst estimates by 83%. Looking ahead, revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Beverage industry in the US. Performance of the American Beverage industry. The company's shares are down 12% from a week ago. Risk Analysis We should say that we've discovered 2 warning signs for Primo Brands (1 shouldn't be ignored!) that you should be aware of before investing here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
